Exploiting crosstalk between estrogen receptors and p53 signaling
Research in the Das Laboratory at Roswell Park Comprehensive Cancer Center focuses on the role of interaction between estrogen receptors (ER) and tumor suppressor protein p53 signaling in breast, ovarian, and lung cancers. Our primary focus is breast cancer.
Our recent findings challenge the accepted dogma regarding the use of endocrine therapy drugs like tamoxifen. The potential to repurpose tamoxifen to treat triple negative breast cancer (TNBC) in combination with chemotherapeutic and immunotherapeutic agents is an exciting opportunity – and the Das Lab is at the forefront of this exciting research.
Research focus: Novel therapeutics for breast cancer
Although ER and p53 have been studied separately over past three decades, the effect of interaction between these two proteins and crosstalk between respective signaling pathways on various biological phenomena – including the onset and progression of cancer and its therapeutic implications – is just beginning to be understood.
Luminal breast cancer
Our findings have important clinical implications in stratifying ERα-positive breast cancer patients to those who would and would not respond to tamoxifen therapy.Read the research
Triple negative breast cancer
We’re learning that combination of tamoxifen and chemotherapy is very effective in inhibiting xenograft TNBC tumor growth in vivo.See the science
We’re looking for a postdoc fellow
The Das Lab is looking for a highly motivated postdoctoral fellow to study molecular mechanisms underlying breast cancer and exploit the new findings to develop novel therapeutic strategies in the clinic.View job posting
Uncovering a New Role for Tamoxifen in Triple-Negative Breast Cancers
The Das Lab identified the first known prognostic marker for aggressive TNBC tumors.